Fellows Spotlight: Maximilian Siebert
Research focus: Strengthening of Evidence and Transparency in Clinical Trials and Regulatory Decisions
Can you describe your background and where you came from before the fellowship?
I completed my pharmacy training in Germany, which involved an intensive focus on chemistry and biology - more than I initially expected. However, toward the end of my studies I discovered my passion for clinical epidemiology, which inspired me to further specialize in the field. This led me to pursue a Master's and then a PhD in France. Before starting this fellowship, I worked at the European Commission and spent two years in sunny California doing Meta-Research.
What does your current research focus on, and who do you work with?
My current research, under the mentorship of Florence Bourgeois, focuses on Postmarketing Requirements. While there has been considerable scrutiny on the weakening standards of premarketing drug approvals, the FDA's post-approval requirements remain less understood. We’re also exploring ways to make tracking and monitoring these requirements more sustainable and effective over time.
Why did you choose to pursue this fellowship opportunity?
Before the fellowship, my work was centered on transparency in Clinical Trials and Open Science, intersecting with drug approval processes. What I felt was missing was a specific application of these methods to a well-defined field and this fellowship provided the perfect opportunity to bridge that gap. Additionally, my time in California made me realize I am probably more of an East Coaster.
What is your favorite thing about the center?
The people. Being surrounded by like-minded individuals who share a passion for improving drug regulation is incredibly motivating. On top of that, being connected to the Harvard community has been a constant source of inspiration.
Where do you plan to go next?
I’m aiming for a role in government or academia. Ideally at the intersection of policy and research.
Is there anything else you want to share?
Drop me a line if you want to talk about transparency in drug regulation, health policy or sharing some French book and movie picks.